Telomir-1

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a pre-clinical-stage company with a mission to develop therapeutics targeting the fundamental biology of aging through telomere extension and metal ion regulation. Its lead asset, Telomir-1, has shown promising pre-clinical results in models of aging, Progeria, and Type 2 Diabetes, supporting its ambitious hypothesis. The company's strategy is to advance Telomir-1 into Phase I/II clinical trials by late 2026, targeting a multi-billion dollar market across common age-related and rare genetic diseases, while operating as a pre-revenue public entity.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a pre-clinical-stage company with a mission to develop therapeutics targeting the fundamental biology of aging through telomere extension and metal ion regulation. Its lead asset, Telomir-1, has shown promising pre-clinical results in models of aging, Progeria, and Type 2 Diabetes, supporting its ambitious hypothesis. The company's strategy is to advance Telomir-1 into Phase I/II clinical trials by late 2026, targeting a multi-billion dollar market across common age-related and rare genetic diseases, while operating as a pre-revenue public entity.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a pre-clinical-stage company with a mission to develop therapeutics targeting the fundamental biology of aging through telomere extension and metal ion regulation. Its lead asset, Telomir-1, has shown promising pre-clinical results in models of aging, Progeria, and Type 2 Diabetes, supporting its ambitious hypothesis. The company's strategy is to advance Telomir-1 into Phase I/II clinical trials by late 2026, targeting a multi-billion dollar market across common age-related and rare genetic diseases, while operating as a pre-revenue public entity.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a pre-clinical-stage company with a mission to develop therapeutics targeting the fundamental biology of aging through telomere extension and metal ion regulation. Its lead asset, Telomir-1, has shown promising pre-clinical results in models of aging, Progeria, and Type 2 Diabetes, supporting its ambitious hypothesis. The company's strategy is to advance Telomir-1 into Phase I/II clinical trials by late 2026, targeting a multi-billion dollar market across common age-related and rare genetic diseases, while operating as a pre-revenue public entity.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a pre-clinical-stage company with a mission to develop therapeutics targeting the fundamental biology of aging through telomere extension and metal ion regulation. Its lead asset, Telomir-1, has shown promising pre-clinical results in models of aging, Progeria, and Type 2 Diabetes, supporting its ambitious hypothesis. The company's strategy is to advance Telomir-1 into Phase I/II clinical trials by late 2026, targeting a multi-billion dollar market across common age-related and rare genetic diseases, while operating as a pre-revenue public entity.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a pre-clinical-stage company with a mission to develop therapeutics targeting the fundamental biology of aging through telomere extension and metal ion regulation. Its lead asset, Telomir-1, has shown promising pre-clinical results in models of aging, Progeria, and Type 2 Diabetes, supporting its ambitious hypothesis. The company's strategy is to advance Telomir-1 into Phase I/II clinical trials by late 2026, targeting a multi-billion dollar market across common age-related and rare genetic diseases, while operating as a pre-revenue public entity.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a pre-clinical-stage company with a mission to develop therapeutics targeting the fundamental biology of aging through telomere extension and metal ion regulation. Its lead asset, Telomir-1, has shown promising pre-clinical results in models of aging, Progeria, and Type 2 Diabetes, supporting its ambitious hypothesis. The company's strategy is to advance Telomir-1 into Phase I/II clinical trials by late 2026, targeting a multi-billion dollar market across common age-related and rare genetic diseases, while operating as a pre-revenue public entity.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a pre-clinical-stage company with a mission to develop therapeutics targeting the fundamental biology of aging through telomere extension and metal ion regulation. Its lead asset, Telomir-1, has shown promising pre-clinical results in models of aging, Progeria, and Type 2 Diabetes, supporting its ambitious hypothesis. The company's strategy is to advance Telomir-1 into Phase I/II clinical trials by late 2026, targeting a multi-billion dollar market across common age-related and rare genetic diseases, while operating as a pre-revenue public entity.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a pre-clinical-stage company with a mission to develop therapeutics targeting the fundamental biology of aging through telomere extension and metal ion regulation. Its lead asset, Telomir-1, has shown promising pre-clinical results in models of aging, Progeria, and Type 2 Diabetes, supporting its ambitious hypothesis. The company's strategy is to advance Telomir-1 into Phase I/II clinical trials by late 2026, targeting a multi-billion dollar market across common age-related and rare genetic diseases, while operating as a pre-revenue public entity.

Therapeutic Areas